T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$2.57B |
| 2 |
GE Aerospace
GE
|
+$1.8B |
| 3 |
UnitedHealth
UNH
|
+$1.63B |
| 4 |
Marriott International
MAR
|
+$1.62B |
| 5 |
Apple
AAPL
|
+$1.3B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$2.87B |
| 2 |
JPMorgan Chase
JPM
|
+$1.64B |
| 3 |
Nike
NKE
|
+$1.59B |
| 4 |
Becton Dickinson
BDX
|
+$1.46B |
| 5 |
Alibaba
BABA
|
+$1.32B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.97% |
| 2 | Healthcare | 18.52% |
| 3 | Consumer Discretionary | 13.26% |
| 4 | Financials | 12.08% |
| 5 | Communication Services | 10.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
826
Axsome Therapeutics
AXSM
$11.2B
| $43.9M | 0.01% |
745,360
-861,631
| -54% | -$70.2M |
|
|
BERY
827
DELISTED
Berry Global Group, Inc.
BERY
| $43.6M | 0.01% |
1,408,828
-14,425
| -1% | -$529K |
|
828
T. Rowe Price
TROW
$23.7B
| $43.6M | 0.01% |
446,010
+36,594
| +9% | +$4.48M |
|
|
GWPH
829
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $43.3M | 0.01% |
494,611
-225,289
| -31% | -$23.9M |
|
830
CRISPR Therapeutics
CRSP
$5.22B
| $42.9M | 0.01% |
1,011,203
-98,969
| -9% | -$5.11M |
|
831
Allogene Therapeutics
ALLO
$683M
| $42.9M | 0.01% |
2,204,534
-265,976
| -11% | -$6.34M |
|
832
Prudential Financial
PRU
$43B
| $42.7M | 0.01% |
819,068
+60,668
| +8% | +$4.82M |
|
833
Winmark
WINA
$1.26B
| $42.6M | 0.01% |
334,078
-2,863
| -0.8% | -$537K |
|
834
ResMed
RMD
$32.9B
| $42.5M | 0.01% |
288,803
+22,443
| +8% | +$3.57M |
|
835
Ubiquiti
UI
$35.3B
| $42.2M | 0.01% |
297,794
-4,823
| -2% | -$736K |
|
|
AZPN
836
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $42.1M | 0.01% |
442,980
+6,632
| +2% | +$631K |
|
|
CSW
837
CSW Industrials
CSW
$5.59B
| $41.6M | 0.01% |
641,238
-42,966
| -6% | -$3.11M |
|
838
Realty Income
O
$59.6B
| $41.3M | 0.01% |
855,314
+107,201
| +14% | +$7.47M |
|
839
Preferred Bank
PFBC
$1.28B
| $41.3M | 0.01% |
1,221,533
-57,434
| -4% | -$3M |
|
840
Blackbaud
BLKB
$2.1B
| $41.2M | 0.01% |
741,625
-2,864
| -0.4% | -$203K |
|
841
Encompass Health
EHC
$12.2B
| $41.1M | 0.01% |
807,110
-2,644
| -0.3% | -$152K |
|
842
Fastenal
FAST
$58.9B
| $41.1M | 0.01% |
2,627,294
+205,214
| +8% | +$3.61M |
|
|
HONE
843
DELISTED
HarborOne Bancorp
HONE
| $41M | 0.01% |
5,446,446
+793,564
| +17% | +$7.95M |
|
844
ACI Worldwide
ACIW
$5.42B
| $41M | 0.01% |
1,697,781
+74,624
| +5% | +$2.38M |
|
845
J&J Snack Foods
JJSF
$1.7B
| $41M | 0.01% |
338,456
+8,108
| +2% | +$1.31M |
|
|
THR
846
DELISTED
Thermon Group Holdings
THR
| $40.8M | 0.01% |
2,705,311
+65,616
| +2% | +$1.37M |
|
|
ISBC
847
DELISTED
Investors Bancorp, Inc.
ISBC
| $40.6M | 0.01% |
5,086,132
-106,415
| -2% | -$1.14M |
|
848
Tidewater
TDW
$4.55B
| $40.6M | 0.01% |
5,736,217
+1,769,741
| +45% | +$23.8M |
|
849
Liberty Energy
LBRT
$3.45B
| $40.4M | 0.01% |
15,032,868
+2,471,977
| +20% | +$17.3M |
|
850
Dorman Products
DORM
$3.95B
| $40.4M | 0.01% |
730,859
-24,569
| -3% | -$1.67M |
|
Similar funds
T. Rowe Price Associates's Q1 2020 Portfolio in Review
As of Q1 2020, T. Rowe Price Associates held 2,612 positions worth $632B, down 18% from $771B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2020 filing shows 87 new, 1,525 increased, 823 reduced and 103 closed positions. Its largest new stake was Philips: 33,363,001 shares worth $1.07B. The largest sale was Boeing, an estimated $2.87B.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 21% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2020 buy was Philips: 33,363,001 shares worth $1.07B.
- T. Rowe Price Associates added most to Humana in Q1 2020, an estimated $2.57B increase.
- T. Rowe Price Associates's biggest Q1 2020 reduction was Boeing, cutting an estimated $2.87B.
- T. Rowe Price Associates fully exited Wellcare Health Plans, Inc. in Q1 2020, selling an estimated $846M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $632B portfolio in Q1 2020.
- T. Rowe Price Associates opened 87 new positions and closed 103 in Q1 2020.
- T. Rowe Price Associates's portfolio value fell 18% quarter-over-quarter to $632B.
Based on T. Rowe Price Associates's 13F filing for Q1 2020, filed 15 May 2020.